Seven Fleet Capital Management LP Acquires New Position in Compass Therapeutics, Inc. $CMPX

Seven Fleet Capital Management LP acquired a new stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 233,066 shares of the company’s stock, valued at approximately $510,415,000.

Other institutional investors have also recently bought and sold shares of the company. Parallel Advisors LLC bought a new stake in shares of Compass Therapeutics during the 1st quarter valued at $28,000. Russell Investments Group Ltd. boosted its position in shares of Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after purchasing an additional 7,592 shares during the last quarter. Xponance LLC bought a new position in shares of Compass Therapeutics in the 4th quarter worth $55,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Compass Therapeutics during the third quarter worth $37,000. Finally, PNC Financial Services Group Inc. grew its stake in shares of Compass Therapeutics by 2,572.6% during the first quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company’s stock worth $58,000 after purchasing an additional 10,625 shares during the period. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $2.43 on Thursday. Compass Therapeutics, Inc. has a one year low of $1.61 and a one year high of $6.88. The firm has a market cap of $437.62 million, a P/E ratio of -6.08 and a beta of 0.92. The stock’s 50-day moving average is $2.17 and its 200-day moving average is $3.50.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities analysts anticipate that Compass Therapeutics, Inc. will post -0.47 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on CMPX shares. Citigroup reissued a “market outperform” rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. Wall Street Zen lowered Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Piper Sandler upped their price target on Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Stifel Nicolaus set a $6.00 price target on shares of Compass Therapeutics in a research report on Monday, June 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.77.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.